• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears Ascensia’s Contour Next One blood glucose monitor

November 21, 2016 By Sarah Faulkner

FDA clears Ascenia's Contour Next One blood glucose monitorAscensia Diabetes Care said today that it won FDA 510(k) clearance for its Contour Next One blood glucose monitoring system.

The connected system features a blood glucose meter that links to mobile devices using Bluetooth through the Contour Diabetes app. The app can collect, store and analyze the patient’s blood glucose measurements for patterns and trends to help patients understand how their everyday activities affect their blood glucose levels.

The Parsippany, N.J.-based company anticipates that the Contour Next One system will be available in the U.S. at the start of 2017.

Users can set up a cloud-based account to manage and store their data and can also email PDF summary reports to their healthcare professional. The system can remind and alert users to help support better management of diabetes, including an electronic logbook where a patient can record events such as meals and medication.

“This is an innovative new option for people living with diabetes. The system combines the remarkable accuracy of the Contour Next One meter with the easy-to-use features of the Contour Diabetes app and is designed to provide insights that may help people manage their diabetes in a better way,” head of Ascensia Diabetes Care U.S. Robert Schumm said in prepared remarks. “We believe the future of healthcare lies in connecting points of care. The first step in that journey for diabetes is to provide a connected system which can add value for people living with diabetes. Today, fewer than 2% of people living with diabetes use a connected meter. Contour Next One is designed to be simple-to-use, and can meet the needs of a broad group of users. The FDA clearance paves the way to providing this option for all those who may benefit from it.”

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Ascensia Diabetes Care

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS